Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
March 30, 2021 at 10:25 am
Share
Realcan Pharmaceutical Group Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 27,203.883 million compared to CNY 35,258.509 million a year ago. Operating income was CNY 954.474 million compared to CNY 129.721 million a year ago. Net income was CNY 261.302 million compared to net loss of CNY 927.802 million a year ago. Basic earnings per share from continuing operations was CNY 0.21 compared to basic loss per share from continuing operations of CNY 0.62 a year ago.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
REALCAN PHARMACEUTICAL GROUP CO., LTD. 
